Metacrine, Inc. – NASDAQ:MTCR

Add to watchlist

$0.551

-0.03

-5.23%

Market closed

Open in 2 days

+2.37%

month

+2.35%

quarter

+23.62%

year

Market Cap	N/A
Enterprise value	N/A

P/E	-0.39
EV/Sales	N/A
EV/EBITDA	0.61
Price/Sales	N/A
Price/Book	0.42
PEG ratio	N/A
EPS	-0.93

Revenue	N/A
EBITDA	-36.04M
Income	-39.32M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Metacrine, Inc. (NASDAQ:MTCR): Profit margin
Dec 2021	0	-13.98M
Mar 2022	0	-13.24M
Jun 2022	0	-6.75M
Sep 2022	0	-5.32M

Metacrine, Inc. (NASDAQ:MTCR): Debt to assets
Dec 2021	79989000	22.63M	28.3%
Mar 2022	66736000	20.28M	30.4%
Jun 2022	59141000	17.65M	29.86%
Sep 2022	55037000	17.97M	32.65%

Metacrine, Inc. (NASDAQ:MTCR): Cash Flow
Dec 2021	-11.83M	17.15M	26.56M
Mar 2022	-13.69M	-2.17M	0
Jun 2022	-7.88M	20.2M	1K
Sep 2022	-2.79M	10.2M	0

Metacrine alternative data

Metacrine, Inc. (NASDAQ:MTCR): Employee count
Aug 2023	10
Sep 2023	10
Oct 2023	10
Nov 2023	10
Dec 2023	10
Jan 2024	10
Feb 2024	10
Mar 2024	10
Apr 2024	10
May 2024	10
Jun 2024	10
Jul 2024	10

Metacrine
Hedge Funds Holdings Q1 2023

21.26% -16.98%

of MTCR is owned by hedge funds

4 -23

hedge funds hold MTCR stock

9.05M -7.22M

shares is hold by hedge funds

MTCR hedge funds holdings changes

Metacrine, Inc. (NASDAQ:MTCR): Insider trades (number of shares)
Period	Buy	Sel
Apr 2022	0	44748
Oct 2022	2074695	0
Nov 2022	164270	0
Dec 2022	271605	0
Jan 2023	0	487659

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	26 Jan 2023	KLASSEN PRESTON director, officer..	Common Stock	380,605	$0.41	$157,190
Sale	26 Jan 2023	YORK MICHAEL officer: Chief Business Officer officer: Chief Business Officer	Common Stock	107,054	$0.41	$44,320
Purchase	21 Dec 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	120,099	$0.4	$48,040
Purchase	20 Dec 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	50,122	$0.38	$18,996
Purchase	19 Dec 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	101,384	$0.4	$40,554
Purchase	9 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	39,816	$0.39	$15,528
Purchase	8 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	500	$0.4	$200
Purchase	7 Nov 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	123,954	$0.42	$52,309
Purchase	28 Oct 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	45,022	$0.4	$18,009
Purchase	27 Oct 2022	LEONARD BRADEN MICHAEL 10 percent owner 10 percent owner	Common Stock	767,507	$0.39	$299,328

Status	Patent	Filling date	Issue date
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 30 Nov 2021 Issue date: 24 Mar 2022	30 Nov 2021	24 Mar 2022
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 22 Nov 2021 Issue date: 17 Mar 2022	22 Nov 2021	17 Mar 2022
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 17 Sep 2019 Issue date: 24 Feb 2022	17 Sep 2019	24 Feb 2022
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 17 Sep 2019 Issue date: 24 Feb 2022	17 Sep 2019	24 Feb 2022
Application	Application FARNESOID X RECEPTOR AGONISTS FOR THE TREATMENT OF DISEASE Filling date: 17 Sep 2019 Issue date: 17 Feb 2022	17 Sep 2019	17 Feb 2022
Application	Application SSAO INHIBITORS AND USES THEREOF Filling date: 23 Oct 2019 Issue date: 6 Jan 2022	23 Oct 2019	6 Jan 2022
Grant	Grant Utility: Farnesoid X receptor agonists and uses thereof Filling date: 12 May 2020 Issue date: 4 Jan 2022	12 May 2020	4 Jan 2022
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 16 Jun 2021 Issue date: 23 Dec 2021	16 Jun 2021	23 Dec 2021
Application	Application CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST Filling date: 17 Sep 2019 Issue date: 11 Nov 2021	17 Sep 2019	11 Nov 2021
Application	Application FARNESOID X RECEPTOR AGONISTS AND USES THEREOF Filling date: 19 Jan 2021 Issue date: 30 Sep 2021	19 Jan 2021	30 Sep 2021

Metacrine
Executives

Insider	Age	Compensation
Dr. Preston S. Klassen (1969) Pres, Chief Executive Officer & Director	56	$522,510
Ms. Patricia M. Millican (1973) Chief Financial Officer	52	$496,090
Ms. Catherine C. Lee (1974) Executive Vice President, Gen. Counsel & Corporation Sec.	51	$383,320

Metacrine
Latest News

Monday, 26 December 2022
14:20	Trading Penny Stocks Under $1: Strategies for Succes & 7 To Watch	PennyStocks
Thursday, 15 December 2022
05:42	Metacrine: Potential Play On A Higher Bid	Seeking Alpha
Friday, 11 February 2022
11:55	Metacrine To Slash Its Workforce By 50%	Benzinga
Monday, 20 December 2021
09:59	Is the Options Market Predicting a Spike in Metacrine (MTCR) Stock?	Zacks Investment Research
Wednesday, 15 December 2021
15:52	3 Penny Stocks To Watch After Jerome Powell's Fed Announcement	PennyStocks
Thursday, 9 September 2021
08:05	Metacrine Achieves Full Enrollment for MET642 Phase 2a Trial in Patients With Nash	GlobeNewsWire
Wednesday, 8 September 2021
08:05	Metacrine to Host Virtual R&D Day for Analysts and Investors on September 15, 2021	GlobeNewsWire
Tuesday, 7 September 2021
08:05	Metacrine to Present at H.C. Wainwright 23rd Annual Global Investment Conference	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 15 Dec 2022

Metacrine: Potential Play On A Higher Bid

Frequently Asked Questions (FAQ)

What's the price of Metacrine stock today?

One share of Metacrine stock can currently be purchased for approximately $0.55.
When is Metacrine's next earnings date?

Unfortunately, Metacrine's (MTCR) next earnings date is currently unknown.
Does Metacrine pay dividends?

Yes, Metacrine pays dividends and its trailing 12-month yield is 99.76% with 0% payout ratio. The last Metacrine stock dividend of undefined was paid on 6 Sep 2025.
What is Metacrine's stock symbol?

Metacrine, Inc. is traded on the NASDAQ under the ticker symbol "MTCR".
What is Metacrine's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Metacrine?

Shares of Metacrine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Metacrine's key executives?
Metacrine's management team includes the following people:
- Dr. Preston S. Klassen Pres, Chief Executive Officer & Director(age: 56, pay: $522,510)
- Ms. Patricia M. Millican Chief Financial Officer(age: 52, pay: $496,090)
- Ms. Catherine C. Lee Executive Vice President, Gen. Counsel & Corporation Sec.(age: 51, pay: $383,320)
How many employees does Metacrine have?

As Jul 2024, Metacrine employs 10 workers.
When Metacrine went public?

Metacrine, Inc. is publicly traded company for more then 4 years since IPO on 16 Sep 2020.
What is Metacrine's official website?

The official website for Metacrine is metacrine.com.
Where are Metacrine's headquarters?

Metacrine is headquartered at 3985 Sorrento Valley Boulevard, San Diego, CA.
How can i contact Metacrine?

Metacrine's mailing address is 3985 Sorrento Valley Boulevard, San Diego, CA and company can be reached via phone at 858 369 7800.

Metacrine, Inc.

metacrine.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

858 369 7800

3985 Sorrento Valley Boulevard
San Diego, CA 92121

CIK: 0001634379
ISIN: US59101E1038
CUSIP: 59101E103